Most bio-industries are built on an assumption that doesn't hold globally: that freshwater is abundant. We build feedstock infrastructure where it isn't.
How it works ↓Desert organisms evolved to store, bind, protect, and structure with minimal water. We cultivate them at scale — and turn the harvest into verified feedstock for energy, materials, and food-grade applications.
Polyculture systems anchored on Opuntia ficus-indica — a CAM plant that produces wet biomass at commercial yields with no irrigation. Companion species fix nitrogen and restore soil. The result is a productive, resilient plantation on land conventional agriculture cannot use.
Drone-based LiDAR and photogrammetry produce tamper-evident, blockchain-registered biomass records for every plot. Our monitoring layer is designed to meet the auditability requirements of carbon registries, renewable energy certification, and industrial supply chain compliance.
A single Opuntia harvest yields multiple concurrent value streams — energy feedstock, food-grade material fractions, and fibre. Processed on-site or routed to partner facilities, each fraction is verified against the same biomass record that produced it.
Verified outputs reach industrial partners across energy, materials, and carbon markets. We coordinate multi-industry offtake from a shared feedstock base — so no single partner needs to carry the full plantation infrastructure alone.
Water scarcity is structural, not cyclical. The regions where it is most acute — semi-arid Southern Africa, the Mediterranean, Central Asia, the Asia-Pacific interior — are also the regions with the most available land and the least productive use of it. Xeropim treats that intersection as an opportunity: to build biorefinery feedstock infrastructure that doesn't depend on rainfall abundance, and to make the output of that infrastructure auditable, certifiable, and commercially viable for the partners who need it.
Our pilot is in Limpopo, South Africa. Our ambition is the regions like it.
For pilot partnerships, industrial offtake, monitoring and MRV inquiries, research collaboration, and investment conversations.